Race Oncology Begins Patient Enrollment in Australia for RC220 Phase 1 Clinical Trial; Shares Up 6%

MT Newswires Live

2025/04/03

Race Oncology (ASX:RAC) began patient enrollment at Southside Cancer Care Center in Miranda, New South Wales for the Phase 1 clinical trial of RC220 in advanced solid tumors, according to a Thursday filing with the Australian bourse.

It will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose in combination with doxorubicin, and effects on a range of clinical biomarkers, the filing stated.

The open-label phase one trial will be conducted across multiple sites in Australia, Hong Kong, and South Korea, per the filing.

Race Oncology's shares were up 6% in recent trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2524299426"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524299426\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2524299426?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-03 08:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524299426","market":"fut","top_or_hot":-1,"title":"Race Oncology Begins Patient Enrollment in Australia for RC220 Phase 1 Clinical Trial; Shares Up 6%","media":"MT Newswires Live","content":"<html><body><p> Race Oncology (ASX:RAC) began patient enrollment at Southside Cancer Care Center in Miranda, New South Wales for the Phase 1 clinical trial of RC220 in advanced solid tumors, according to a Thursday filing with the Australian bourse.</p><p>It will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose in combination with doxorubicin, and effects on a range of clinical biomarkers, the filing stated.</p><p>The open-label phase one trial will be conducted across multiple sites in Australia, Hong Kong, and South Korea, per the filing.</p><p>Race Oncology's shares were up 6% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Race Oncology Begins Patient Enrollment in Australia for RC220 Phase 1 Clinical Trial; Shares Up 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRace Oncology Begins Patient Enrollment in Australia for RC220 Phase 1 Clinical Trial; Shares Up 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-03 08:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Race Oncology (ASX:RAC) began patient enrollment at Southside Cancer Care Center in Miranda, New South Wales for the Phase 1 clinical trial of RC220 in advanced solid tumors, according to a Thursday filing with the Australian bourse.</p><p>It will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose in combination with doxorubicin, and effects on a range of clinical biomarkers, the filing stated.</p><p>The open-label phase one trial will be conducted across multiple sites in Australia, Hong Kong, and South Korea, per the filing.</p><p>Race Oncology's shares were up 6% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2524299426","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524299426","pubTimestamp":1743639566,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Race Oncology  began patient enrollment at Southside Cancer Care Center in Miranda, New South Wales for the Phase 1 clinical trial of RC220 in advanced solid tumors, according to a Thursday filing with the Australian bourse.It will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose in combination with doxorubicin, and effects on a range of clinical biomarkers, the filing stated.The open-label phase one trial will be conducted across multiple sites in Australia, Hong Kong, and South Korea, per the filing.Race Oncology's shares were up 6% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","RAC.AU":"RACE ONCOLOGY LTD","XAO.AU":"标普/澳交所 普通股指数","XKO.AU":"标普/澳交所 300指数","XJO.AU":"标普/澳交所 200指数"},"translate_title":"Race Oncology开始在澳大利亚招募RC220 1期临床试验的患者；股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":0.9,"XJO.AU":1,"XAO.AU":1,"XKO.AU":1},"content_text":"Race Oncology (ASX:RAC) began patient enrollment at Southside Cancer Care Center in Miranda, New South Wales for the Phase 1 clinical trial of RC220 in advanced solid tumors, according to a Thursday filing with the Australian bourse.It will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose in combination with doxorubicin, and effects on a range of clinical biomarkers, the filing stated.The open-label phase one trial will be conducted across multiple sites in Australia, Hong Kong, and South Korea, per the filing.Race Oncology's shares were up 6% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}